

Downregulation of CENPK Suppresses Hepatocellular Carcinoma Malignant Progression through Regulating YAPI [Corrigendum]

Wang J, Li H, Xia C, et al. *Onco Targets Ther.* 2019;12:869–882.

The authors have advised Figure 2E on page 874 is incorrect. Due to an error at the time of figure assembly NC (24 h) and shCENPK (48 h) in the SMMC-7721 row were inadvertently duplicated. The correct Figure 2 is as follows.




Figure 2 Silencing of CENPK inhibits HCC cell growth, migration, and invasion in vitro.

Notes: (A) Expression of CENPK in BEL-7404 and SMMC-7721 cells was confirmed by qRT-PCR and Western blotting after transfection with shCENPK lentivirus or shNC. (B) Proliferation rate of BEL-7404 and SMMC-7721 cells was measured over 4 days by the CCK-8 assay. (C and D) Representative images (C) and quantification (D) of the colony formation assays are shown for BEL-7404 and SMMC-7721 cells. (E) Analysis of migration in BEL-7404 and SMMC-7721 cells as measured by wound healing assays ($\times 200$). (F and G) Analysis of invasion in BEL-7404 and SMMC-7721 cells as measured by transwell assays. (F) Representative photographs ($\times 200$). (G) Number of invaded cells was counted in five randomly selected areas. Scale bar = 100 μ m. NC represents negative control group (shNC), and shCENPK represents downregulation of CENPK group. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.

Abbreviations: qRT-PCR, quantitative real-time PCR; CCK-8, Cell Counting Kit-8; NC, negative control.

The authors apologize for this error and advise it does not affect the results of the paper.

OncoTargets and Therapy**Dovepress****Publish your work in this journal**

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>